The Go Medical Therapy Radiopharmaceutical Infusion Pump (TRIP) Kit is designed to facilitate safe intravenous administration of non-particulate radiopharmaceuticals to patients where high radioactivity pharmaceutical are to be used and/or there is a need for very slow radioactive infusions. The kit enables the radiopharmaceuticals to be administered from a sealed serum vial contained within a lead pot shield, which has a slotted lid to allow access by tubing and needles.

Product History

A design team comprising Dr. O’Neil, Dr. Harvey Turner and engineers, included Mr. Chin Tark Chan, worked to develop components that would allow the preparation of rituximab and radioactive iodine-131 in the laboratory or pharmacy of Australian teaching hospitals.

The TRIP kit has been specifically designed to facilitate the preparation of rituximab and radioactive iodine-131 in the laboratory or pharmacy. The radioactive labelled rituximab is then delivered to the patient via an intravenous infusion pump connected via a secondary infusion line. The TRIP Kit has been designed to work with the Abbott Lifecare 5000 pump, fitted with an Abbott Primary Intravenous Pump Set-SL.

The concept and development phase for the research team occurred between 2002 and 2003 when Dr. Harvey Turner initially started his work at Fremantle Hospital.

Intended Use

It is designed to facilitate safe intravenous administration of the non-particulate radio-pharmaceuticals to patients when high activities are to be used and/or there is a need for very slow radioactive infusions.  This is a highly specialised procedure carried out by trained hospital staff.

Indications

To facilitate intravenous administration of non-particulate radiopharmaceuticals to patients when high activities are to be used and/or there is a need for very slow radioactive infusions. The kit enables the radiopharmaceuticals to be administered from a sealed serum vial contained within a lead pot shield, which has a slotted lid to allow access by tubing and needles.

Contraindications

There are no known contraindications associated with TRIP kit when it is used within the specific context for which it was designed. 

Device Variants

Clinical Data Sources

The following papers have evaluated the techniques used in radio immunotherapy that the TRIP Kit has been developed specifically for.                                                                                              

1. Bishton, M.J. et al., 2008. A prospective study of the separate predictive capabilities of 18[F]-FDG-PET and molecular response in patients with relapsed indolent non-Hodgkin’s lymphoma following treatment with iodine-131-rituximab radio-immunotherapy. Haematologica, 93(5), pp.789–90. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18450737
2. Bishton, M.J. et al., 2008. Repeat treatment with iodine-131-rituximab is safe and effective in patients with relapsed indolent B-cell non-Hodgkin’s lymphoma who had previously responded to iodine-131-rituximab. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 19(9), pp.1629–33. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18522934
3. Claringbold, P.G. et al., 2011. Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours. European journal of nuclear medicine and molecular imaging, 38(2), pp.302–11. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21052661
4. Leahy, M.F. et al., 2006. Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin’s lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24(27), pp.4418–25. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16940276
5. Leahy, M.F. & Turner, J.H., 2011. Radioimmunotherapy of relapsed indolent non-Hodgkin lymphoma with 131I-rituximab in routine clinical practice: 10-year single-institution experience of 142 consecutive patients. Blood, 117(1), pp.45–52. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20864582
6. Turner, J.H. et al., 2003. 131I-Anti CD20 radioimmunotherapy of relapsed or refractory non-Hodgkins lymphoma: a phase II clinical trial of a nonmyeloablative dose regimen of chimeric rituximab radiolabeled in a hospital. Cancer biotherapy & radiopharmaceuticals, 18(4), pp.513–24. Available at: http://www.ncbi.nlm.nih.gov/pubmed/14503945
7. Turner, J.H., 2009. Defining pharmacokinetics for individual patient dosimetry in routine radiopeptide and radioimmunotherapy of cancer: Australian experience. Current pharmaceutical design, 15(9), pp.966–82. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19275661
8. Turner, J.H., 2012. Outpatient therapeutic nuclear oncology. Annals of nuclear medicine, 26(4), pp.289–97. Available at: http://link.springer.com/10.1007/s12149-011-0566-z